Realtime | Geld | Brief | Zeit |
---|---|---|---|
0,192 | 0,212 | 06.06. | |
0,192 | 0,210 | 06.06. |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
BRII BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
Di | BRII-B (02137): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
Di | BRII-B (02137): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 3, 2025 AND CHANGE IN COMPOSITION OF THE NOMINATION COMMITTEE | 1 | HKEx | ||
29.05. | No. of COVID-19 Cases Hikes, Triggering Speculation in Related Pharma; CSPC PHARMA/JUNSHI BIO/SIMCERE PHARMA/BRII-B Surge 10%+ | 8 | AASTOCKS | ||
08.05. | BRII-B (02137): VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE | 1 | HKEx | ||
28.04. | BRII-B (02137): CLARIFICATION ANNOUNCEMENT (1) CHANGE OF DATE OF ANNUAL GENERAL MEETING; AND (2) CHANGE OF CLOSURE OF THE REGISTER OF MEMBERS | 1 | HKEx | ||
25.04. | BRII-B (02137): NOTIFICATION LETTER AND REQUEST FORM FOR NON-REGISTERED SHAREHOLDERS | 1 | HKEx | ||
25.04. | BRII-B (02137): NOTIFICATION LETTER AND CHANGE REQUEST FORM FOR REGISTERED SHAREHOLDERS | - | HKEx | ||
25.04. | BRII-B (02137): 2024 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | - | HKEx | ||
25.04. | BRII-B (02137): FORM OF PROXY FOR USE AT THE ANNUAL GENERAL MEETING | - | HKEx | ||
25.04. | BRII-B (02137): NOTICE OF ANNUAL GENERAL MEETING | 1 | HKEx | ||
25.04. | BRII-B (02137): (1) PROPOSALS FOR ADOPTION OF THE AUDITED CONSOLIDATED FINANCIAL STATEMENTS; (2) RE-ELECTION OF RETIRING DIRECTORS; (3) RE-APPOINTMENT ... | - | HKEx | ||
25.04. | BRII-B (02137): 2024 ANNUAL REPORT | - | HKEx | ||
07.04. | BRII-B (02137): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
30.03. | Brii Biosciences Limited: Brii Bio Unveils New Data from Its Ongoing Phase 2 ENSURE Study at APASL 2025, Showcasing BRII-179's Unique Potential to Prime and Boost Higher HBsAg Loss Through Target Patient Identification | 47 | PR Newswire | Preliminary data from Cohort 4 of the ENSURE study supports a novel enrichment strategy to utilize BRII-179 to identify patients who are immune responders and... ► Artikel lesen | |
21.03. | Brii Biosciences Limited: Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results | 132 | PR Newswire | Strategic Acquisition of Intellectual Property of BRII-179, a Wholly Owned Phase 2b Asset Capable of Combining with Multiple HBV Treatment Modalities for Cure
Data... ► Artikel lesen | |
21.03. | BRII-B (02137): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2024 AND CHANGE IN USE OF PROCEEDS | 1 | HKEx | ||
21.03. | BRII-B (02137): NOTIFICATION OF 2024 PFIC STATUS | - | HKEx | ||
10.03. | BRII-B (02137): DATE OF BOARD MEETING | - | HKEx | ||
15.01. | BRII-B (02137): NEXT DAY DISCLOSURE RETURN | 4 | HKEx | ||
10.01. | BRII-B (02137): SUPPLEMENTAL ANNOUNCEMENT DISCLOSEABLE TRANSACTION IN RELATION TO NOMINEE DESIGNATION AGREEMENT | 1 | HKEx |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIOGEN | 116,70 | -0,09 % | DAX tritt auf der Stelle - Nvidia & Biogen mit Überraschung! Gold, EUR & Aktien im Chartcheck | ||
ILLUMINA | 72,45 | -0,10 % | Does Illumina (ILMN) Have Good Long-Term Growth Prospects? | ||
NANOREPRO | 1,675 | -1,18 % | EQS-DD: NanoRepro AG: Dr. Olaf Stiller, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
26.05.2025 / 14:00... ► Artikel lesen | |
BRAIN BIOTECH | 2,100 | +0,48 % | BRAIN Biotech: Wann kommt die Trendwende bei den Biokatalysatoren? | Die BRAIN Biotech AG (DE0005203947) kämpft mit einem schwierigen Marktumfeld. Im ersten Halbjahr 2024/25 ging der Umsatz um 7,2 Prozent auf 25,2 Millionen Euro zurück. Das Unternehmen spürt die Auswirkungen... ► Artikel lesen | |
BIONXT SOLUTIONS | 0,369 | +3,36 % | Unterbewertete Healthcare Titel - BioNxt Solutions, Evotec, Novo Nordisk | Wie der Einkaufsmanager-Index in der Euro-Zone zeigt, erholt sich die Stimmung in der Industrie von Südeuropa langsam. Schlusslicht bleibt dabei die Zuversicht der Geschäftsführer der größten deutschen... ► Artikel lesen | |
INFLARX | 0,750 | +2,46 % | Evotec, GFT Technologies, InflaRx, Nordex, Rheinmetall, ThyssenKrupp - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem gibt Finanzierung mittels Wandelschuldverschreibung bekannt | Vancouver, British Columbia, 22. April 2025 / IRW-Press / Sirona Biochem Corp. (TSX-V: SBM) (FWB: ZSB) (OTC: SRBCF) ("Sirona" oder das "Unternehmen") gibt eine nicht vermittelte Privatplatzierung... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 0,524 | -0,38 % | Defence Therapeutics Inc.: Defence Therapeutics Opens U.S. Laboratory in Boston-Cambridge Biotech Hub | Montreal, Quebec--(Newsfile Corp. - June 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in advanced... ► Artikel lesen | |
TREVENA | 0,153 | 0,00 % | Delisting of Securities of Patria Latin American Opportunity Acquisition Corp.; Trevena, Inc.; Seelos Therapeutics, Inc.; DP Cap Acquisition Corp I; Chain Bridge I; Qomolangma Acquisition Corp.; Gaucho Group Holdings, Inc. ... | NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the Class A Ordinary Shares, unit, and warrant of Patria Latin American Opportunity Acquisition... ► Artikel lesen | |
BURCON NUTRASCIENCE | 0,073 | +5,80 % | Burcon NutraScience Corporation: Burcon to Participate in 2025 Canadian Climate Investor Conference | Vancouver, British Columbia--(Newsfile Corp. - May 28, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in the development of... ► Artikel lesen | |
CYTODYN | 0,282 | 0,00 % | CytoDyn Inc.: CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer | VANCOUVER, Washington, May 06, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential... ► Artikel lesen | |
TME PHARMA | 0,089 | 0,00 % | TME Pharma N.V.: TME Pharma Provides Additional Details on the Debt and Warrant Agreements Announced on 21 May That Extend Its Financial Visibility by 12 Months | The Company is hereby clarifying and providing additional information on the financing announced on May 21, 2025 TME Pharma has secured private binding commitments from professional European... ► Artikel lesen | |
IMMUNIC | 0,698 | +1,16 % | EQS-News: Immunic AG: Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS | Issuer: Immunic AG
/ Key word(s): Study/Study results
Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining... ► Artikel lesen | |
PHIO PHARMACEUTICALS | 2,960 | +20,33 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA Portfolio | - Robert Infarinato named VP, Strategic Development- Lisa Carson named as new VP, Finance and AdministrationMarlborough, Massachusetts--(Newsfile Corp. - June 6, 2025) - Phio Pharmaceuticals Corp.... ► Artikel lesen | |
IOVANCE BIOTHERAPEUTICS | 1,798 | +0,21 % | Goldman Sachs bekräftigt Kaufempfehlung für Iovance-Aktie nach ASCO-Daten |